+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors



Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors



Cancer Research 71(13): 4344-4351



The phosphoinositide 3-kinase (PI3K) signaling cascade, a key mediator of cellular survival, growth, and metabolism, is frequently altered in human cancer. Activating mutations in PIK3CA, which encodes the α-catalytic subunit of PI3K, occur in approximately 30% of breast cancers. These mutations result in constitutive activity of the enzyme and are oncogenic, but it is not known whether they are sufficient to induce mammary carcinomas in mice. In the present study, we show that the expression of mutant PIK3CA H1047R in the luminal mammary epithelium evokes heterogeneous tumors that express luminal and basal markers and are positive for the estrogen receptor. Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R.

(PDF emailed within 0-6 h: $19.90)

Accession: 054194901

Download citation: RISBibTeXText

PMID: 21482677

DOI: 10.1158/0008-5472.CAN-10-3827


Related references

Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. Plos One 7(5): E36924-E36924, 2012

Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Research 73(13): 4075-4085, 2013

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America 110(35): 14372-7, 2013

Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. Plos Computational Biology 10(10): E1003895-E1003895, 2015

Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. Febs Journal 280(12): 2758-2765, 2013

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget 4(9): 1484-1495, 2014

Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. Developmental Biology 404(1): 14-26, 2015

Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochemical Journal 458(2): 251-258, 2014

A Long-Lived Luminal Subpopulation Enriched with Alveolar Progenitors Serves as Cellular Origin of Heterogeneous Mammary Tumors. Stem Cell Reports 5(1): 60-74, 2016

Expression by transgenesis of a constitutively active mutant form of the prolactin receptor induces premature abnormal development of the mouse mammary gland and lactation failure. Biology of Reproduction 70(3): 718-728, 2003

Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. American Journal of Pathology 168(3): 973-990, 2006

PI3K/mTOR Inhibitors in Cancers with PIK3CA H1047R Mutation. 2013